
## Stephanie David

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1630605/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 157, 74-84.	4.3	13
2	Homogeneous distribution of fatty esterâ€based active cosmetic ingredients in hydrophilic thin films by means of nanodispersion. International Journal of Cosmetic Science, 2020, 42, 512-519.	2.6	8
3	gH625 Cell-Penetrating Peptide Promotes the Endosomal Escape of Nanovectorized siRNA in a Triple-Negative Breast Cancer Cell Line. Biomacromolecules, 2019, 20, 3076-3086.	5.4	20
4	Magnetic nanocarriers for the specific delivery of siRNA: Contribution of breast cancer cells active targeting for down-regulation efficiency. International Journal of Pharmaceutics, 2019, 569, 118572.	5.2	21
5	Model Affitin and PEG modifications onto siRNA lipid nanocapsules: cell uptake and in vivo biodistribution improvements. RSC Advances, 2019, 9, 27264-27278.	3.6	11
6	Versatile electrostatically assembled polymeric siRNA nanovectors: Can they overcome the limits of siRNA tumor delivery?. International Journal of Pharmaceutics, 2019, 567, 118432.	5.2	19
7	Fluorescence Microscopy as a Tool for Nanomedicine-Cell Interactions Study: Input of Particle Design and of Analytical Strategy. Microscopy and Microanalysis, 2018, 24, 1316-1317.	0.4	0
8	Formulation and in vitro evaluation of a siRNA delivery nanosystem decorated with gH625 peptide for triple negative breast cancer theranosis. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 131, 99-108.	4.3	41
9	Stealth magnetic nanocarriers of siRNA as platform for breast cancer theranostics. International Journal of Pharmaceutics, 2017, 532, 660-668.	5.2	18
10	siRNA delivery system based on magnetic nanovectors: Characterization and stability evaluation. European Journal of Pharmaceutical Sciences, 2017, 106, 287-293.	4.0	16
11	Modelling the response surface to predict the hydrodynamic diameters of theranostic magnetic siRNA nanovectors. International Journal of Pharmaceutics, 2015, 478, 409-415.	5.2	7
12	Use of experimental design methodology for the development of new magnetic siRNA nanovectors (MSN). International Journal of Pharmaceutics, 2013, 454, 660-667.	5.2	10
13	EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro. International Journal of Pharmaceutics, 2013, 454, 748-755.	5.2	20
14	DNA Nanocarriers for Systemic Administration: Characterization and In Vivo Bioimaging in Healthy Mice. Molecular Therapy - Nucleic Acids, 2013, 2, e64.	5.1	20
15	Treatment efficacy of DNA lipid nanocapsules and DNA multimodular systems after systemic administration in a human glioma model. Journal of Gene Medicine, 2012, 14, 769-775.	2.8	13
16	siRNA LNCs – A novel platform of lipid nanocapsules for systemic siRNA administration. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 448-452.	4.3	30
17	In vivo imaging of DNA lipid nanocapsules after systemic administration in a melanoma mouse model. International Journal of Pharmaceutics, 2012, 423, 108-115.	5.2	28
18	Nature as a source of inspiration for cationic lipid synthesis. Genetica, 2010, 138, 153-168.	1.1	30

		STEPHANIE DAVID		
#	Article	IF	CITATIONS	
19	Non-viral nanosystems for systemic siRNA delivery. Pharmacological Research, 2010, 62, 100-114.	7.1	100	